uniQure (NASDAQ:QURE) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of uniQure (NASDAQ:QURE) in a report issued on Tuesday,Benzinga reports. The firm currently has a $70.00 price target on the biotechnology company’s stock.

Other research analysts have also issued reports about the company. Wells Fargo & Company dropped their price objective on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, November 12th. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Stifel Nicolaus decreased their price objective on shares of uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Royal Bank Of Canada dropped their price objective on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. Finally, Benchmark reissued a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $58.33.

uniQure Stock Down 5.1%

Shares of QURE stock opened at $24.71 on Tuesday. uniQure has a twelve month low of $7.76 and a twelve month high of $71.50. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The stock’s 50 day simple moving average is $23.42 and its 200 day simple moving average is $29.06. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -5.63 and a beta of 0.66.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. As a group, research analysts predict that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling at uniQure

In other news, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director owned 20,439 shares in the company, valued at $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of QURE. Swiss National Bank bought a new stake in uniQure in the second quarter valued at about $1,080,000. Sanders Morris Harris LLC acquired a new position in shares of uniQure during the 3rd quarter worth about $5,081,000. Jennison Associates LLC bought a new stake in shares of uniQure in the 2nd quarter valued at about $1,952,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of uniQure in the 2nd quarter valued at approximately $872,000. Finally, JPMorgan Chase & Co. boosted its stake in uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after acquiring an additional 1,491,486 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.